Friday, February 16, 2018 3:34:57 PM
We spoke a bit about competition in the arena of personal immune systems contributing to individualized cancer vaccines. he acknowledged that there certainly is competition, though we didn't speak specifically about the stanford research. Roger did say he believed TLT's patented vaccine technology is very robust. Also mentioned jv with larger pharma as possible avenue, but obviously nothing more specific on that...
Obviously a longshot for a tiny company like TLT to be the one and only to find THE cancer grail, but even if not 1st to market, if it works as well as or better than others even if only for certain specific cancers, it will be a game-changer for TLT...and hopeful cancer patients. Ways to go before we find that out...
In the meantime, the bladder trials, then if successful, other cancer types with broader/larger patient base...
btw, you could be helpful by sending roger the link you posted ...or perhaps you have already done so...
rwhite@theralase.com
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM